585 related articles for article (PubMed ID: 16579002)
41. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
[TBL] [Abstract][Full Text] [Related]
42. Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition.
Vora JP; Leese GP; Peters JR; Owens DR
J Diabetes Complications; 1996; 10(2):88-93. PubMed ID: 8777336
[TBL] [Abstract][Full Text] [Related]
43. Transforming growth factor beta at clinical onset of Type 1 diabetes mellitus. A pilot study.
Flores L; Näf S; Hernáez R; Conget I; Gomis R; Esmatjes E
Diabet Med; 2004 Aug; 21(8):818-22. PubMed ID: 15270783
[TBL] [Abstract][Full Text] [Related]
44. Effects of captopril on urinary excretion of albumin and prostaglandins in patients with diabetic nephropathy.
Tajiri Y; Umeda F; Inoguchi T; Kunisaki M; Nawata H; Ninomiya H; Asano T
Diabetes Res; 1990 Mar; 13(3):145-50. PubMed ID: 2091882
[TBL] [Abstract][Full Text] [Related]
45. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
46. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Agha A; Amer W; Anwar E; Bashir K
Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
[TBL] [Abstract][Full Text] [Related]
47. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
48. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy.
Ngarmukos C; Bunnag P; Kosachunhanun N; Krittiyawong S; Leelawatana R; Prathipanawatr T; Plengvidhya N; Benjasuratwong Y; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Mongkolsomlit S; Rawdaree P
J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S37-42. PubMed ID: 17715832
[TBL] [Abstract][Full Text] [Related]
49. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy.
Aggarwal HK; Jain D; Talapatra P; Yadav RK; Gupta T; Kathuria KL
Ren Fail; 2010; 32(8):941-6. PubMed ID: 20722561
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
52. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
53. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
[TBL] [Abstract][Full Text] [Related]
54. Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
Sohn EJ; Kim CS; Kim YS; Jung DH; Jang DS; Lee YM; Kim JS
Life Sci; 2007 Jan; 80(5):468-75. PubMed ID: 17070554
[TBL] [Abstract][Full Text] [Related]
55. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
[TBL] [Abstract][Full Text] [Related]
56. Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications.
Agarwal R
Am J Nephrol; 2007; 27(1):92-100. PubMed ID: 17284896
[TBL] [Abstract][Full Text] [Related]
57. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N
Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907
[TBL] [Abstract][Full Text] [Related]
58. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
59. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
Saikawa T; Sasaki J; Biro S; Kono S; Otonari T; Ikeda Y;
Hypertens Res; 2010 Sep; 33(9):886-91. PubMed ID: 20555331
[TBL] [Abstract][Full Text] [Related]
60. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
